MOSHE TALPAZ, MD
Osteopathic Medicine in Ann Arbor, MI

License number

Michigan 4301086684

Personal information

See more information about MOSHE TALPAZ at radaris.com

Name

Address

Phone

Moshe Talpaz, age 77

305 Rock Creek Ct, Ann Arbor, MI 48104

Moshe Talpaz

305 Rock Creek Ct, Ann Arbor, MI 48104

Professional information

See more information about MOSHE TALPAZ at trustoria.com

Moshe Talpaz, Ann Arbor MI

Specialties:

Internal Medicine, Medical Oncology, Hematology & Oncology, Hematology

Work:

University of Michigan Medical School
1500 E Medical Center Dr, Ann Arbor, MI 48109 Regents of the University of Michigan
1051 N Canton Center Rd, Canton, MI 48187 Univ. of Texas M.D. Anderson C.
1515 Holcombe Blvd, Houston, TX 77030

Education:

Hebrew University, Hadassah Medical School (1975)

Dr. Moshe Talpaz, Ann Arbor MI - MD (Doctor of Medicine)

Specialties:

Oncology, Medical Oncology

Address:

Univers Of Mich Comp Canc Ctr
1500 E Medical Center Dr, Ann Arbor 48109
(734) 647-8901 (Phone)

Certifications:

Internal Medicine, 1982, Medical Oncology, 1983

Awards:

Healthgrades Honor Roll

Languages:

English

Hospitals:

Univers Of Mich Comp Canc Ctr
1500 E Medical Center Dr, Ann Arbor 48109
University of Michigan Health System
1500 East Medical Center Dr SPC 5474, Ann Arbor 48109

Education:

Medical School
The Hebrew University / Hadassah Medical School

Deubiquitinase Inhibitors And Methods For Use Of The Same

US Patent:

2012007, Mar 29, 2012

Filed:

Sep 23, 2011

Appl. No.:

13/241802

Inventors:

Nicholas J. Donato - Ann Arbor MI, US
Christiane Wobus - Dexter MI, US
Hollis D. Showalter - Ann Arbor MI, US
Moshe Talpaz - Ann Arbor MI, US
Jeffrey W. Perry - Ypsilanti MI, US
Roderick J. Sorenson - Ann Arbor MI, US
Mary X. O'Riordan - Ann Arbor MI, US
Yafei Jin - Ann Arbor MI, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI

International Classification:

A61K 31/541, C12N 5/02, A61K 31/5377, A61K 31/53, A61K 31/50, C07D 413/12, A61K 31/496, A61K 31/505, A61K 31/454, A61K 31/4439, A61K 31/44, A61K 31/433, A61K 31/4245, A61K 31/426, A61K 31/42, A61K 31/4164, A61K 31/415, A61K 31/165, C07D 417/12, C07D 253/065, C07D 253/04, C07D 237/06, C07D 239/02, A61K 31/4965, C07D 401/12, C07D 213/57, C07D 285/06, C07D 285/12, C07D 271/10, C07D 277/30, C07D 261/06, C07D 233/90, C07D 231/10, C07C 255/32, A61P 25/28, A61P 31/04, A61P 31/10, A61P 31/12, A61P 33/00, A61P 35/00, C12N 9/99

US Classification:

5142278, 435184, 435375, 5142372, 514241, 514242, 514247, 5142521, 51425301, 514256, 514326, 514341, 514357, 514361, 514363, 514364, 514365, 514378, 514400, 514406, 514620, 544 60, 544131, 544182, 544215, 544224, 544335, 544336, 544360, 546210, 5462764, 546330, 548127, 548136, 548143, 548204, 548247, 5483361, 5483751, 558392

Abstract:

Disclosed herein are methods of inhibiting a deubiquitinase (DUB), methods of treating pathogenic infections (e.g., viral, bacterial, and/or parasitic), methods of inhibiting cell proliferation, methods of treating a neurodegenerative disease, methods of treating one or more symptoms of a neurodegenerative disease or a genetic disorder, and compounds.